Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nan Jing, China Clinical Trials

A listing of Nan Jing, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

Phase

0.0 miles

Learn More »

Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

Although many therapies exist and are being developed to relieve symptoms for colon cancer, there are few randomized controlled clinical trials to evaluate comprehensive Traditional Chinese medicine (TCM) interventions in colon cancer. The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy ...

Phase

0.0 miles

Learn More »

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

The assessment of cognitive scales included Minimum Mental State Examination(MMSE), Alzheimer's Disease Assessment Scale-cognition(ADAS-cog), Neuropsychiatric inventory(NPI), quality of Life of Life in Alzheimer's disease(Qol-ADL), activities of Daily living(ADL), Geriatric Depression scale(GDS).Biochemical test included cholesterol, triglycerides, and low density lipoprotein.

Phase

0.11 miles

Learn More »

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens ...

Phase

0.68 miles

Learn More »

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

UC is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops ulcers. Guselkumab is a fully human immunoglobulin G1 lambda monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high affinity. The study is designed to answer scientific questions pertaining ...

Phase

0.68 miles

Learn More »

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered Locally Advanced or Metastatic Triple-Negative Breast Cancer or Hormone Receptor-Positive HER2-Negative Breast Cancer

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2) breast adenocarcinoma who ...

Phase

0.94 miles

Learn More »

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases

This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced NSCLC with CNS metastases. Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-nave advanced NSCLC and documented intracranial disease ...

Phase

0.94 miles

Learn More »

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

In June 2017, this study was revised to expand the Phase 2 part to enroll more subjects and remove the Phase 3 part under the same protocol. A Phase 3 study will be initiated separately.

Phase

1.78 miles

Learn More »

Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB

IL-2 therapy regimans are expected to restore the immune response or to change the immunologic status,thus allowing the host to more efficiently contain and eradicate immune responses, primarily those against cancers and infectious diseases.To address this, we performed a prospective randomized controlled multicenter cohort study of 8-month adjunctive immunotherapy with ...

Phase

2.28 miles

Learn More »

PF-06651600 for the Treatment of Alopecia Areata

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive ...

Phase

2.28 miles

Learn More »